New diabetes combo drug put to the test – but trial on hold

NCT ID NCT07433062

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is studying whether an experimental drug called AZD6793 changes how the common diabetes medicine metformin works in people with type 2 diabetes. About 28 participants will take both AZD6793 and a placebo alongside their usual metformin to compare effects on blood sugar levels. The study is currently suspended, and because it is small and early, it is mainly about safety and drug interactions, not a proven new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6793 (an experimental drug) and metformin (a standard diabetes medication)
What this could lead to: If it works, this could help understand whether AZD6793 can be safely combined with metformin to improve blood sugar control.
What could go wrong: This is a very early Phase 1 trial with only 28 participants, and it is currently suspended. It is designed to check drug interactions, not to prove effectiveness, so results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Research Site

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.